After 6 months , we found no significant differences between the omega-3 and placebo groups in the number of patients with decreased ALT by 0.3 times the ULN ( 24 vs 23 ) or in median ( IQR ) ALT activity ( 48.5 [ 31-62 ] U/L vs 39 [ 27-55 ] U/L ) , liver hyperechogenicity , insulin resistance , or serum lipid levels .